Market revenue in 2023 | USD 3,343.5 million |
Market revenue in 2030 | USD 7,683.0 million |
Growth rate | 12.6% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.84% in 2023. Horizon Databook has segmented the North America immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in funding for neurological biomarker research is expected to drive the market in North America. Furthermore, growing R&D expenditure, advanced healthcare infrastructure, and large number of pharmaceutical companies are boosting the market in North America.
Supportive government initiatives, such as collaborations between the U.S. and Brazil on biomedical research to accelerate R&D in the diagnosis and treatment of chronic diseases, are aiding the market growth.
Poor reimbursement structure for biomarker testing may hinder market growth. Political instability and the U.S.-China trade war may act as threats for the market.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America immunoassay for neurological biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into North America immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account